Paramesu Biotech files Rs 600 crore IPO papers with Sebi
Paramesu Biotech Ltd, a leading manufacturer of maize-based products, recently filed for an IPO to raise Rs 600 crore. The company plans to use the funds for expansion and debt repayment. Paramesu Biotech has a strong market presence in India and ...

Proceeds from the fresh issue worth Rs 330 crore will be used for setting up a new plant of 1,200 TPD (tonnes per day) in Madhya Pradesh, Rs 85 crore for payment of debt and the rest towards general corporate purposes.
The company is equipped with a current installed capacity of 800 TPD.
With a high capacity utilisation rate of 93 per cent in FY 2024.
Paramesu Biotech is one of the largest manufacturers of maize-based speciality products in India. The diversified product portfolio includes native maize starch, modified maize starches, liquid glucose, maltodextrin powder, and co-products such as germs, gluten, fiber, corn steep liquor and enriched fiber, among others.
Operating from its Devarapalli facility in Andhra Pradesh, the company maintains a strong presence in both domestic and international markets, with products available across 14 states, four union territories and more than 10 countries in Southeast Asia and the Middle East.
On the financial front, the company's revenue rose to Rs 628 crore in FY24 from Rs 495 crore in FY22, while Profit After Tax grew to Rs 40 crore in FY24 from Rs 34 crore in FY22.
Pantomath Capital Advisors is the sole book-running lead manager to the issue.
Download ET Markets APP